Literature DB >> 18246196

Making a bad thing worse: adverse effects of stress on drug addiction.

Jessica N Cleck1, Julie A Blendy.   

Abstract

Sustained exposure to various psychological stressors can exacerbate neuropsychiatric disorders, including drug addiction. Addiction is a chronic brain disease in which individuals cannot control their need for drugs, despite negative health and social consequences. The brains of addicted individuals are altered and respond very differently to stress than those of individuals who are not addicted. In this Review, we highlight some of the common effects of stress and drugs of abuse throughout the addiction cycle. We also discuss both animal and human studies that suggest treating the stress-related aspects of drug addiction is likely to be an important contributing factor to a long-lasting recovery from this disorder.

Entities:  

Mesh:

Year:  2008        PMID: 18246196      PMCID: PMC2214707          DOI: 10.1172/JCI33946

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  125 in total

1.  Chronic cocaine administration sensitizes behavioral but not neuroendocrine responses.

Authors:  B Borowsky; C M Kuhn
Journal:  Brain Res       Date:  1991-03-15       Impact factor: 3.252

2.  'Normal' cigarette smoking increases free cortisol in habitual smokers.

Authors:  C Kirschbaum; S Wüst; C J Strasburger
Journal:  Life Sci       Date:  1992       Impact factor: 5.037

3.  Corticosterone levels determine individual vulnerability to amphetamine self-administration.

Authors:  P V Piazza; S Maccari; J M Deminière; M Le Moal; P Mormède; H Simon
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-15       Impact factor: 11.205

4.  Effects of specific mu and kappa opiate tolerance and abstinence on hypothalamo-pituitary-adrenal axis secretion in the rat.

Authors:  D M Ignar; C M Kuhn
Journal:  J Pharmacol Exp Ther       Date:  1990-12       Impact factor: 4.030

5.  Adaptation of the hypothalamic-pituitary-adrenal axis to chronic ethanol stress.

Authors:  R L Spencer; B S McEwen
Journal:  Neuroendocrinology       Date:  1990-11       Impact factor: 4.914

6.  Stimulatory effect of cocaine on ACTH secretion: role of the hypothalamus.

Authors:  C Rivier; S Lee
Journal:  Mol Cell Neurosci       Date:  1994-04       Impact factor: 4.314

7.  Intravenous cocaine challenges during desipramine maintenance.

Authors:  T Kosten; F H Gawin; D G Silverman; J Fleming; M Compton; P Jatlow; R Byck
Journal:  Neuropsychopharmacology       Date:  1992-11       Impact factor: 7.853

8.  Microinjection of a corticotropin-releasing factor antagonist into the central nucleus of the amygdala reverses anxiogenic-like effects of ethanol withdrawal.

Authors:  S Rassnick; S C Heinrichs; K T Britton; G F Koob
Journal:  Brain Res       Date:  1993-03-05       Impact factor: 3.252

9.  Alterations of corticotropin-releasing factor-like immunoreactivity in different brain regions after acute cocaine administration in rats.

Authors:  Z Sarnyai; E Bíró; J Gardi; M Vecsernyés; J Julesz; G Telegdy
Journal:  Brain Res       Date:  1993-07-09       Impact factor: 3.252

10.  Naltrexone in the treatment of alcohol dependence.

Authors:  J R Volpicelli; A I Alterman; M Hayashida; C P O'Brien
Journal:  Arch Gen Psychiatry       Date:  1992-11
View more
  46 in total

Review 1.  Neuroendocrinology of reward in anorexia nervosa and bulimia nervosa: Beyond leptin and ghrelin.

Authors:  Laura A Berner; Tiffany A Brown; Jason M Lavender; Emily Lopez; Christina E Wierenga; Walter H Kaye
Journal:  Mol Cell Endocrinol       Date:  2018-11-02       Impact factor: 4.102

2.  Physiological systems under pressure.

Authors:  Andrew R Marks
Journal:  J Clin Invest       Date:  2008-02       Impact factor: 14.808

3.  Blunted stress reactivity in chronic cannabis users.

Authors:  Carrie Cuttler; Alexander Spradlin; Amy T Nusbaum; Paul Whitney; John M Hinson; Ryan J McLaughlin
Journal:  Psychopharmacology (Berl)       Date:  2017-05-31       Impact factor: 4.530

4.  Glucocorticoid receptors participate in the opiate withdrawal-induced stimulation of rats NTS noradrenergic activity and in the somatic signs of morphine withdrawal.

Authors:  Javier Navarro-Zaragoza; Juana M Hidalgo; M Luisa Laorden; M Victoria Milanés
Journal:  Br J Pharmacol       Date:  2012-08       Impact factor: 8.739

5.  Morphine withdrawal stress modulates lipopolysaccharide-induced interleukin 12 p40 (IL-12p40) expression by activating extracellular signal-regulated kinase 1/2, which is further potentiated by glucocorticoids.

Authors:  Subhas Das; Jennifer Kelschenbach; Richard Charboneau; Roderick A Barke; Sabita Roy
Journal:  J Biol Chem       Date:  2011-07-05       Impact factor: 5.157

6.  Elevated glucocorticoid levels are responsible for induction of tyrosine hydroxylase mRNA expression, phosphorylation, and enzyme activity in the nucleus of the solitary tract during morphine withdrawal.

Authors:  Cristina Núñez; Anna Földes; Domingo Pérez-Flores; J Carlos García-Borrón; M Luisa Laorden; Krisztina J Kovács; M Victoria Milanés
Journal:  Endocrinology       Date:  2009-01-29       Impact factor: 4.736

Review 7.  Chronic stress, drug use, and vulnerability to addiction.

Authors:  Rajita Sinha
Journal:  Ann N Y Acad Sci       Date:  2008-10       Impact factor: 5.691

Review 8.  Amphetamine recapitulates developmental programs in the zebrafish.

Authors:  Jean Lud Cadet
Journal:  Genome Biol       Date:  2009-07-31       Impact factor: 13.583

9.  Kappa opioid receptors regulate stress-induced cocaine seeking and synaptic plasticity.

Authors:  Nicholas M Graziane; Abigail M Polter; Lisa A Briand; R Christopher Pierce; Julie A Kauer
Journal:  Neuron       Date:  2013-03-06       Impact factor: 17.173

10.  Integrated programs for women with substance use issues and their children: a qualitative meta-synthesis of processes and outcomes.

Authors:  Wendy Sword; Susan Jack; Alison Niccols; Karen Milligan; Joanna Henderson; Lehana Thabane
Journal:  Harm Reduct J       Date:  2009-11-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.